November 2019 - Antwerp, Belgium

Meeting objectives:

  • Provide an overview of the current situation of the HPV vaccine for adults.
  • Discuss the immunogenicity, safety and efficacy data of existing HPV vaccine studies in adults.
  • Gain insight into the efficacy of the HPV vaccine at the mucosal level and systemic level.
  • Discuss ways and methods to conduct research on the potential benefits of vaccinating exposed adults.
  • Discuss the challenges and benefits of vaccination of adults including high risk groups.
  • Discuss cervical cancer elimination strategies.
  • Discuss the potential implications of vaccination of adults on vaccine supplies in Low and Middle-Income Countries (LMIC).

Background document 

November 14, 2019

OPENING AND OBJECTIVES

SESSION 1: SITUATIONAL ANALYSIS OF HPV VACCINATION OF ADULTS: IMUNOGENECITY AND SAFETY DATA
Chairs: Alex Vorsters & Pierre Van Damme

SESSION 2: HPV IMMUNOLOGICAL DYNAMICS AT MUCOSAL AND SYSTEMIC LEVEL
Chairs: Mario Poljak & Marc Arbyn

SESSION 3: COMPREHENSIVE ANALYSIS OF CHALLENGES AND POTENTIAL BENEFITS OF HPV VACCINATION OF ADULTS
Chairs:  Eduardo Franco & Iacopo Bausanno

November 15, 2019

SESSION 4: HPV VACCINATION OF HIGH-RISK GROUPS
Chairs: Mira Kojouharova & Sharon Hanley​

SESSION 5: LIMITATIONS AND ELIMINATION GOALS
Chairs: Mark Kane & Luidmila Mosina

BREAKOUT SESSIONS
Chairs:  Paul Bloem & Emilie Karafillakis

   - Outcome of the meeting, current challenges and strategies to deal with challenges: Where do we stand today? 

  • Plenary feedback from each group and discussion

CONCLUSION OF THE MEETING
Chairs: Pierre Van Damme & Xavier Bosch

  • Conclusion (Pdf, 213.74 kB)
     
  • Closing remarks